Why are there no proper phase 3 trials for RU Chat 3/17/2026
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity If RU58841 is such an effective anti androgen
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
community Finasteride alternative close to fda approval in the US
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.
community RU55481
The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.
community Peter h diamandis Dr David Sinclair podcast
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.
community Why are there no FDA approved NSAA's yet?
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
Related Research
6 / 6 results
research Investigational medications in the treatment of alopecia
This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.
research Title Choice of treatment for severe forms of alopecia areata (case reports)
This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.
research A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention
This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.
research Alopecia areata in children: an overview of clinical features and recent treatment options
This source highlights that the incidence of alopecia areata is increasing among children, and while corticosteroids and Janus kinase inhibitors show potential effectiveness and safety, they remain unapproved by the FDA for pediatric use.
research Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.